Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia’s Clinuvel Says Phase III Trial Of UV-Blocking Drug A Success

This article was originally published in PharmAsia News

Executive Summary

Australia's Clinuvel reports Phase III success for its afamelanotide drug for a rare genetic disorder that causes a skin intolerance to ultraviolet radiation and light. The trial, Clinuvel said, showed the EPP drug significantly reduced the severity of phototoxic reaction. It works by stimulating melanin production to absorb ultraviolet radiation. The trials were conducted in Switzerland and similar trials are expected to take place later this year in Europe and Australia. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069874

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel